Effect of Radiation Therapy Among Head and Neck Cancer Patients on the Inner Ear Function
Evaluation of the Effect of Radiation Therapy Among Head and Neck Cancer Patients on the Inner Ear Function Using Novel Techniques
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Yahav Oron, MD
- Phone Number: 973236973573
- Email: oron.yahav@gmail.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Females and males, Age: ≥ 18 years old
- Patients diagnosed Head and Neck cancers, not treated previously
- Planned for radiation therapy in which the inner ear will be radiated
Exclusion Criteria:
- Patients who were previously diagnosed with a vestibular disorder
- Previous middle or inner ear anomaly
- Failure to complete the whole course of radiation therapy
- More than one course of radiation therapy
- Patients treated with concurrent ototoxic chemotherapy
- Pregnant women
- Patients who will not sign an informed consent form
- Helpless or incompetent patients
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Head and Neck Cancer patients
|
Diagnostic tests
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Audiometry
Time Frame: 1.5 Year
|
The change in hearing threshold and in the speech-audiometry
|
1.5 Year
|
|
ENG test
Time Frame: 1.5 Year
|
Abnormal function of the central vestibular pathways, unilateral weakness of the vestibular apparatus or direction preponderance
|
1.5 Year
|
|
VEMP test
Time Frame: 1.5 Year
|
Abnormal latencies, amplitudes, thresholds
|
1.5 Year
|
|
vHIT test
Time Frame: 1.5 Year
|
abnormal gain, the appearance of overt and covert saccades
|
1.5 Year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 403-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer Patients Treated With Radiotherapy
-
NCT06879366CompletedHead and Neck Cancer Patients Treated With Radiotherapy
-
NCT07300631RecruitingProstate Cancer Patients Treated by Radiotherapy
-
NCT01960751CompletedPatients Treated by Radiotherapy With < One Gy to the Brain
-
NCT02484677Completed
-
NCT07254416Not yet recruitingBreast Cancer Patients Treated With T-DXd
-
NCT01980498WithdrawnPredictable BTP at Swallowing in in Head/Neck Cancer Patients Undergoing Radiotherapy Already Receiving Opioid Therapy for Background Pain
-
NCT07561346CompletedHER2 Low and HER2 Zero Patients With Operable Breast Cancer Treated With Dds-CT
-
NCT07132749Enrolling by invitationNEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd (PRO-NEPA)Patients With HER2-positive Advanced Breast Cancer Treated With T-DXd | Patients With HER2-low Advanced Breast Cancer Treated With T-DXd
-
NCT05046028CompletedHead and Neck Cancer | Radiotherapy; Complications
-
NCT03194061UnknownRadiotherapy; Complications